Nurix Therapeutics, Inc. (NRIX)

Market Cap	758.08M
Revenue (ttm)	80.89M
Net Income (ttm)	-144.73M
Shares Out	59.32M
EPS (ttm)	-2.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	465,539
Open	13.15
Previous Close	12.73
Day's Range	12.70 - 13.73
52-Week Range	4.22 - 18.12
Beta	2.06
Analysts	Buy
Price Target	21.86 (+71.05%)
Earnings Date	Apr 10, 2024

About NRIX

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 24, 2020
• Employees: 284
• Stock Exchange: NASDAQ
• Ticker Symbol: NRIX

Financial Performance

In 2023, NRIX's revenue was $76.99 million, an increase of 99.31% compared to the previous year's $38.63 million. Losses were -$143.95 million, -20.19% less than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for NRIX stock is "Buy." The 12-month stock price forecast is $21.86, which is an increase of 71.05% from the latest price.

Price Target

$21.86

(71.05% upside)

Analyst Consensus: Buy